logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Carcinoma Renal Cell

    Medications for Carcinoma Renal Cell

    FiltersReset Filters
    5 results

    • inlyta

      (axitinib)
      U.S. Pharmaceuticals
      Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.

    • pazopanib

      (pazopanib hydrochloride)
      Novugen Pharma (USA) LLC.
      Usage: Pazopanib tablets are indicated for adults with advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Efficacy for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.

    • pazopanib

      (Pazopanib)
      SUN PHARMACEUTICAL INDUSTRIES, INC.
      Usage: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors.

    • sorafenib

      (Sorafenib)
      Teva Pharmaceuticals Inc
      Usage: Sorafenib tablets are indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

    • temsirolimus

      (temsirolimus)
      Accord Healthcare Inc.
      Usage: Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.